Dr. Tina Garyantes, Vice President of Innovation at Chromocell, presented at the 245th Meeting & Exposition of the American Chemical Society that took place this April in New Orleans. Dr. Garyantes’ presentation focused on the value of running a phenotypic and a targeted or pathway specific screen in parallel rather than sequentially. She showed that parallel screening can both improve data confidence and provide complementary data that will speed up the candidate discovery process.
Dr. Garyantes joined the Chromocell team in January, 2013. Prior to joining Chromocell, she was CEO of MaxSAR; focusing on a high throughput approach to expanding chemical diversity. Past experience also includes her time as the global head of assay development and screening at Sanofi; focusing on phenotypic and image based screening with therapeutic responsibilities in Fibrosis and Oncology.
Prior to joining Sanofi, Dr. Garyantes invented the virtual well plate at Merck and developed the first clinical instrument for fine structure analysis of DNA at Ciba-Corning Diagnostics.